Man Group’s Ascendis Pharma A/S ASND Stock Holding History

Man Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-103,084	Closed	-$6.46M	–	1949
2018 Q4	$6.46M	Buy	+103,084	New	+$6.48M	0.03%	635

Other funds holding ASND

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Man Group's ASND Position: Q1 2019 in Review

Man Group sold out of Ascendis Pharma A/S (ASND) in Q1 2019, closing a stake of 103,084 shares — an estimated $6.46M sold.

Man Group first reported a position in ASND in Q4 2018 and held it in 1 quarter. The position peaked at $6.46M in Q4 2018. 138 funds tracked by Wall St. Rank hold ASND as of Q1 2019.

Man Group reported no remaining Ascendis Pharma A/S position as of Q1 2019 after selling out during the quarter.
Man Group sold 103,084 Ascendis Pharma A/S shares in Q1 2019, an estimated $6.46M.
Man Group first reported a position in Ascendis Pharma A/S in Q4 2018 and held it in 1 quarter.
Man Group's Ascendis Pharma A/S position peaked at $6.46M in Q4 2018.
138 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2019.

Based on Man Group's 13F filing for Q1 2019, filed 15 May 2019.